Hikma completes acquisition of Ben Venue manufacturing site

17th Sep 2014 12:12

Hikma Pharmaceuticals announced on Wednesday the completion of the acquisition for the Ben Venture Laboratories’ manufacturing site.Ben Ventures Laboratories is a subsidary of the Boehringer Ingelheim Pharmaceuticals Group.As agreed on 24 July, Hikma has now acquired ownership of all of the assets of the generic injectables manufacturing site, including four manufacturing plants and a state-of-the-art research and development (R&D) pilot plant.Said Darwazah, chairman and chief executive officer of Hikma, hopes the move will significantly strengthen the company's existing R&D capabilities and facilitate expansion.Hikma’s share price increased 0.99% as of 12:14 on Wednesday.